ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Published Date: June 2025
|
Report Code: QYRE-Auto-24O12722
Home | Market Reports | Health| Health Conditions
Global Duchenne Muscular Dystrophy DMD Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Code: QYRE-Auto-24O12722
Report
June 2025
Pages:126
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sarepta Therapeutics
PTC Therapeutics
Pfizer Inc
Bristol–Myers Squibb
Italfarmaco S.p.A.
Santhera Pharmaceuticals

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size

In 2024, the global market size of Duchenne Muscular Dystrophy (DMD) Therapeutics was estimated to be worth US$ 2670 million and is forecast to reach approximately US$ 30310 million by 2031 with a CAGR of 42.1% during the forecast period 2025-2031.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market

Duchenne Muscular Dystrophy (DMD) Therapeutics Market

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation

Scope of Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report

Report Metric Details
Report Name Duchenne Muscular Dystrophy (DMD) Therapeutics Market
CAGR 42.1%
Segment by Type
  • Exondys
  • Emflaza
  • Translarna
Segment by Application
  • Hospitals
  • Clinics
  • Home Care
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
  • Chapter 2: Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in global and regional level.
  • Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Duchenne Muscular Dystrophy (DMD) Therapeutics revenue, gross margin, and recent development, etc.
  • Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: Research Findings and Conclusion

FAQ for this report

What is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market share by region?

Ans: By region, North America has the highest market share, reaching 70.66% in 2019.

Who are the main players in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report?

Ans: The main players in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market are Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals

What are the Application segmentation covered in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report?

Ans: The Applications covered in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report are Hospitals, Clinics, Home Care

What are the Type segmentation covered in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report?

Ans: The Types covered in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report are Exondys, Emflaza, Translarna

1 Study Coverage
1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Estimates and Forecasts
2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2024 Versus 2031
2.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region: 2020-2025
2.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Region (2026-2031)
2.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2031)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2031)
3.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Exondys of Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application
3.3.2 Emflaza of Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application
3.3.3 Translarna of Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application
4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Company
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2020-2025)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Duchenne Muscular Dystrophy (DMD) Therapeutics Companies around the World: Ranking by Revenue
4.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Headquarters & Product Type
4.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Headquarters
4.4.2 Date of International Companies Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
4.4.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Product & Service
4.4.4 Exondys Revenue Market Share of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company
4.4.5 Emflaza Revenue Market Share of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company
4.4.6 Translarna Revenue Market Share of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company
4.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Sarepta Therapeutics
5.1.1 Sarepta Therapeutics Corporation Information
5.1.2 Sarepta Therapeutics Description, Business Overview
5.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products Offered
5.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2020-2025)
5.1.5 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Product in 2024
5.1.6 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application in 2024
5.1.7 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Geographic Area in 2024
5.1.8 Sarepta Therapeutics Recent Developments
5.2 PTC Therapeutics
5.2.1 PTC Therapeutics Corporation Information
5.2.2 PTC Therapeutics Description, Business Overview
5.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products Offered
5.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2020-2025)
5.2.5 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Product in 2024
5.2.6 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application in 2024
5.2.7 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Geographic Area in 2024
5.2.8 PTC Therapeutics Recent Developments
5.3 Pfizer
5.3.1 Pfizer Corporation Information
5.3.2 Pfizer Description, Business Overview
5.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Products Offered
5.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2020-2025)
5.3.5 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Product in 2024
5.3.6 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application in 2024
5.3.7 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Geographic Area in 2024
5.3.8 Pfizer Recent Developments
5.4 Bristol-Myers Squibb
5.4.1 Bristol-Myers Squibb Corporation Information
5.4.2 Bristol-Myers Squibb Description, Business Overview
5.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Products Offered
5.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2020-2025)
5.4.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Product in 2024
5.4.6 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application in 2024
5.4.7 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Geographic Area in 2024
5.4.8 Bristol-Myers Squibb Recent Developments
5.5 Italfarmaco
5.5.1 Italfarmaco Corporation Information
5.5.2 Italfarmaco Description, Business Overview
5.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Products Offered
5.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2020-2025)
5.5.5 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Product in 2024
5.5.6 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application in 2024
5.5.7 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Geographic Area in 2024
5.5.8 Italfarmaco Recent Developments
5.6 Santhera Pharmaceuticals
5.6.1 Santhera Pharmaceuticals Corporation Information
5.6.2 Santhera Pharmaceuticals Description, Business Overview
5.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Products Offered
5.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2020-2025)
5.6.5 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Product in 2024
5.6.6 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application in 2024
5.6.7 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Geographic Area in 2024
5.6.8 Santhera Pharmaceuticals Recent Developments
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2020-2031
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Country (2020-2031)
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025)
6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025)
7.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025)
8 Europe
8.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2020-2031
8.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Country (2020-2031)
8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025)
8.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2020-2031
9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Country (2020-2031)
9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025)
9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025)
10.4 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Supply Chain Analysis
11.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Raw Materials and Upstream Suppliers
11.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Clients Analysis
11.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Channel and Sales Model Analysis
11.4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Distributors
12 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
12.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
12.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
12.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
FEATURED COMPANIES
Sarepta Therapeutics
PTC Therapeutics
Pfizer Inc
Bristol–Myers Squibb
Italfarmaco S.p.A.
Santhera Pharmaceuticals
List of Tables
 Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2024 VS 2031
 Table 4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Region (2026-2031) & (US$ Million)
 Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Type (2026-2031) & (US$ Million)
 Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Application (2026-2031) & (US$ Million)
 Table 10. Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2020-2025) & (US$ Million)
 Table 11. Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Company (2020-2025)
 Table 12. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (US$ Million) in 2024
 Table 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
 Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
 Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Headquarters
 Table 16. Date of International Companies Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
 Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Product & Service
 Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Mergers & Acquisitions, Expansion Plans
 Table 19. Sarepta Therapeutics Corporation Information
 Table 20. Sarepta Therapeutics Description and Business Overview
 Table 21. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
 Table 22. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 23. Sarepta Therapeutics Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Product in 2024
 Table 24. Sarepta Therapeutics Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Application in 2024
 Table 25. Sarepta Therapeutics Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Geographic Area in 2024
 Table 26. Sarepta Therapeutics Recent Developments
 Table 27. PTC Therapeutics Corporation Information
 Table 28. PTC Therapeutics Description and Business Overview
 Table 29. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
 Table 30. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 31. PTC Therapeutics Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Product in 2024
 Table 32. PTC Therapeutics Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Application in 2024
 Table 33. PTC Therapeutics Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Geographic Area in 2024
 Table 34. PTC Therapeutics Recent Developments
 Table 35. Pfizer Corporation Information
 Table 36. Pfizer Description and Business Overview
 Table 37. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product
 Table 38. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 39. Pfizer Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Product in 2024
 Table 40. Pfizer Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Application in 2024
 Table 41. Pfizer Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Geographic Area in 2024
 Table 42. Pfizer Recent Developments
 Table 43. Bristol-Myers Squibb Corporation Information
 Table 44. Bristol-Myers Squibb Description and Business Overview
 Table 45. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product
 Table 46. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Bristol-Myers Squibb Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Product in 2024
 Table 48. Bristol-Myers Squibb Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Application in 2024
 Table 49. Bristol-Myers Squibb Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Geographic Area in 2024
 Table 50. Bristol-Myers Squibb Recent Developments
 Table 51. Italfarmaco Corporation Information
 Table 52. Italfarmaco Description and Business Overview
 Table 53. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
 Table 54. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 55. Italfarmaco Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Product in 2024
 Table 56. Italfarmaco Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Application in 2024
 Table 57. Italfarmaco Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Geographic Area in 2024
 Table 58. Italfarmaco Recent Developments
 Table 59. Santhera Pharmaceuticals Corporation Information
 Table 60. Santhera Pharmaceuticals Description and Business Overview
 Table 61. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
 Table 62. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 63. Santhera Pharmaceuticals Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Product in 2024
 Table 64. Santhera Pharmaceuticals Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Application in 2024
 Table 65. Santhera Pharmaceuticals Revenue Proportion of Duchenne Muscular Dystrophy (DMD) Therapeutics by Geographic Area in 2024
 Table 66. Santhera Pharmaceuticals Recent Developments
 Table 67. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 68. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 69. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 70. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 71. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (2020-2025) & (US$ Million)
 Table 72. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (2026-2031) & (US$ Million)
 Table 73. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 74. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 75. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 76. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 77. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 78. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 79. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 80. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 81. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 82. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 83. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2020-2025) & (US$ Million)
 Table 84. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2026-2031) & (US$ Million)
 Table 85. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2020-2025) & (US$ Million)
 Table 86. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2020-2025) & (US$ Million)
 Table 87. Duchenne Muscular Dystrophy (DMD) Therapeutics Key Raw Materials, Industry Status and Trend
 Table 88. Duchenne Muscular Dystrophy (DMD) Therapeutics Key Raw Materials and Upstream Suppliers
 Table 89. Duchenne Muscular Dystrophy (DMD) Therapeutics Clients Status and Trend
 Table 90. Duchenne Muscular Dystrophy (DMD) Therapeutics Typical Clients
 Table 91. Duchenne Muscular Dystrophy (DMD) Therapeutics Distributors
 Table 92. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
 Table 93. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
 Table 94. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
 Table 95. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
 Table 96. Research Programs/Design for This Report
 Table 97. Key Data Information from Secondary Sources
 Table 98. Key Data Information from Primary Sources


List of Figures
 Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Picture
 Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
 Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type in 2024 & 2031
 Figure 4. Exondys Product Picture
 Figure 5. Emflaza Product Picture
 Figure 6. Translarna Product Picture
 Figure 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
 Figure 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application in 2024 & 2031
 Figure 9. Hospitals
 Figure 10. Clinics
 Figure 11. Home Care
 Figure 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
 Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Region: 2024 Versus 2031
 Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Region (2020-2031)
 Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share Forecast by Type (2020-2031)
 Figure 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share Forecast by Application (2020-2031)
 Figure 19. Exondys of Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application, 2024 VS 2031
 Figure 20. Emflaza of Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application, 2024 VS 2031
 Figure 21. Translarna of Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application, 2024 VS 2031
 Figure 22. Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Company (2024)
 Figure 23. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Exondys Revenue Proportion by Company in 2024
 Figure 25. Emflaza Revenue Proportion by Company in 2024
 Figure 26. Translarna Revenue Proportion by Company in 2024
 Figure 27. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue 2020-2031 (US$ Million)
 Figure 28. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 29. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 30. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue 2020-2031 (US$ Million)
 Figure 31. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Region (2020-2031)
 Figure 32. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 33. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 34. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 35. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 36. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 37. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 38. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 39. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 40. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 41. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 42. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 43. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Country (2020-2031)
 Figure 44. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
 Figure 45. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
 Figure 46. Duchenne Muscular Dystrophy (DMD) Therapeutics Supply Chain (Upstream and Downstream Market)
 Figure 47. Global Production Market Share of Duchenne Muscular Dystrophy (DMD) Therapeutics Raw Materials by Region in 2024
 Figure 48. Duchenne Muscular Dystrophy (DMD) Therapeutics Distribution Channels
 Figure 49. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Percentage 2020-2031: Indirect Sales VS Direct Sales
 Figure 50. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Percentage 2020-2031: Online Sales VS Offline Sales
 Figure 51. Bottom-up and Top-down Approaches for This Report
 Figure 52. Data Triangulation
 Figure 53. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5900

This license allows only one user to access the PDF.
Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Drugs for Duchenne Muscular Dystrophy DMD Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Duchenne Muscular Dystrophy Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030
Myotonic Dystrophy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Myotonic Dystrophy Treatment Market Research Report 2025
Global Myotonic Dystrophy Drug Market Research Report 2024
Myotonic Dystrophy Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Duchenne Muscular Dystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024
Global Amyotrophic Lateral Sclerosis Therapeutics Market Insights Forecast to 2030
Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Sarcopenia Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hunter Syndrome Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Amyotrophic Lateral Sclerosis ALS Treatment Market Insights Forecast to 2030
Global Myasthenia Gravis Therapies Market Research Report 2024
Myasthenia Gravis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cone rod Dystrophy Treatment Market Research Report 2025
Spinal Muscular Atrophy SMA Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
MSD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Amyotrophic Lateral Sclerosis ALS Market Insights Forecast to 2030

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Z7671
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10V14317
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O5919
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4I19963
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions